Pfizer Inc. (PFE): Price and Financial Metrics


Pfizer Inc. (PFE): $52.31

-0.12 (-0.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PFE POWR Grades


  • Value is the dimension where PFE ranks best; there it ranks ahead of 92.77% of US stocks.
  • The strongest trend for PFE is in Momentum, which has been heading down over the past 179 days.
  • PFE's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

PFE Stock Summary

  • PFE has a higher market value than 99.48% of US stocks; more precisely, its current market capitalization is $296,575,292,881.
  • Pfizer Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.84% of US equities in our set.
  • As for revenue growth, note that PFE's revenue has grown 93.97% over the past 12 months; that beats the revenue growth of 91.33% of US companies in our set.
  • Stocks that are quantitatively similar to PFE, based on their financial statements, market capitalization, and price volatility, are LLY, ABBV, MRK, ASML, and INTC.
  • PFE's SEC filings can be seen here. And to visit Pfizer Inc's official web site, go to www.pfizer.com.

PFE Valuation Summary

  • PFE's price/sales ratio is 5; this is 55.95% lower than that of the median Healthcare stock.
  • PFE's price/sales ratio has moved down 2.9 over the prior 243 months.
  • Over the past 243 months, PFE's price/earnings ratio has gone down 17.6.

Below are key valuation metrics over time for PFE.

Stock Date P/S P/B P/E EV/EBIT
PFE 2021-08-31 5.0 3.7 19.5 20.3
PFE 2021-08-30 5.1 3.7 19.8 20.5
PFE 2021-08-27 5.1 3.7 19.8 20.5
PFE 2021-08-26 5.1 3.8 20.1 20.8
PFE 2021-08-25 5.2 3.8 20.1 20.8
PFE 2021-08-24 5.3 3.9 20.5 21.2

PFE Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at -27.39%.
  • The 2 year cash and equivalents growth rate now stands at -6.56%.
  • Its 5 year net cashflow from operations growth rate is now at -9.4%.
Over the past 34 months, PFE's revenue has gone up $27,429,000,000.

The table below shows PFE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 81,288 32,580 21,979
2021-09-30 63,600 32,291 19,180
2021-06-30 51,637 23,552 13,228
2021-03-31 44,461 15,808 11,091
2020-12-31 41,908 14,403 9,616
2020-09-30 48,648 12,547 8,685

PFE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PFE has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
  • PFE's asset turnover comes in at 0.312 -- ranking 146th of 682 Pharmaceutical Products stocks.
  • XBIT, NERV, and BLUE are the stocks whose asset turnover ratios are most correlated with PFE.

The table below shows PFE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-04 0.312 0.704 0.149
2021-04-04 0.265 0.763 0.116
2020-12-31 0.247 0.793 0.099
2020-09-27 0.282 0.799 0.083
2020-06-28 0.288 0.799 0.181
2020-03-29 0.307 0.799 0.200

PFE Price Target

For more insight on analysts targets of PFE, see our PFE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.03 Average Broker Recommendation 1.8 (Hold)

PFE Stock Price Chart Interactive Chart >

Price chart for PFE

PFE Price/Volume Stats

Current price $52.31 52-week high $61.71
Prev. close $52.43 52-week low $38.93
Day low $51.25 Volume 16,143,200
Day high $52.37 Avg. volume 29,302,072
50-day MA $50.60 Dividend yield 3.06%
200-day MA $50.41 Market Cap 293.51B

Pfizer Inc. (PFE) Company Bio


Pfizer Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products. Pfizer was founded under its original name, Charles Pfizer & Company, in 1849 in Brooklyn, New York by Charles Pfizer and Charles Erhart. The company operates research and development facilities in United States and the United Kingdom and employs over 78,000 individuals worldwide. Some of the company’s more recognizable brands include Advil, Celebrex, Chantix, Chapstick, Dimetapp, Lipitor, Robitussin, and Viagra. Albert Bourla serves as Pfizer’s Chairman of the Board and Chief Executive Officer and the company is headquartered in New York, New York.


PFE Latest News Stream


Event/Time News Detail
Loading, please wait...

PFE Latest Social Stream


Loading social stream, please wait...

View Full PFE Social Stream

Latest PFE News From Around the Web

Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.

4 Pharma Stocks to Buy Even if the Pandemic Ends

Here are four pharma stocks that looks attractive for the long-term.

Faisal Humayun on InvestorPlace | February 24, 2022

Novavax Is a Buy on Recent Developments and Cheap Valuation

NVAX stock is one of the major players in the vaccine market, which is one that is expected to grow substantially over the next few years.

Faizan Farooque on InvestorPlace | February 24, 2022

UPDATE 2-EMA backs Pfizer COVID booster for teens, Moderna shot for ages 6-11

The European Union's health regulator on Thursday backed giving a booster shot of Pfizer and BioNTech's COVID-19 vaccine to adolescents aged 12 and over, as well as the expanded use of Moderna's shot in children ages six to 11. The recommendations by the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use will be followed by final decisions by the European Commission. The moves come after several EU countries already started to offer booster doses of the Pfizer/BioNTech vaccine to teens.

Yahoo | February 24, 2022

Got $5,000? These 2 Growth Stocks Are Down 60% From Their Highs

Buying and holding quality growth stocks can be a surefire way to significantly increase your portfolio's value over the years. Two growth stocks that show lots of promise and are down more than 60% from their 52-week highs are BioNTech SE (NASDAQ: BNTX) and Matterport (NASDAQ: MTTR). Healthcare company BioNTech finished last week at less than $157 per share -- down more than 66% from the $464 it peaked at last Aug. 10, which was just after the release of its second-quarter results.

Yahoo | February 24, 2022

Moderna says booster protection wanes after 9 months

Moderna executives have revealed data showing that the protection afforded by its booster shot will begin to wane after about nine months, regardless of what vaccine a patient had used in the primary series.

Yahoo | February 24, 2022

Read More 'PFE' Stories Here

PFE Price Returns

1-mo -1.67%
3-mo -0.25%
6-mo -3.10%
1-year N/A
3-year 40.78%
5-year 99.90%
YTD -10.01%
2021 66.70%
2020 3.23%
2019 -6.91%
2018 24.82%
2017 15.90%

PFE Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full PFE Dividend History

Continue Researching PFE

Want to see what other sources are saying about Pfizer Inc's financials and stock price? Try the links below:

Pfizer Inc (PFE) Stock Price | Nasdaq
Pfizer Inc (PFE) Stock Quote, History and News - Yahoo Finance
Pfizer Inc (PFE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5584 seconds.